Department of Critical Care Medicine.
Department of Gastrointestinal Surgery II.
Medicine (Baltimore). 2021 Apr 23;100(16):e25619. doi: 10.1097/MD.0000000000025619.
The coronavirus disease (COVID-19) outbreak was first reported in December 2019 in Wuhan, China. Specific information about critically ill COVID-19 patients receiving invasive mechanical ventilation (IMV) is rare.To describe the clinical course and complications of critically ill patients with COVID-19 who received IMV and were successfully weaned from it.This retrospective study included patients admitted to 3 intensive care units (ICUs) and 1 sub-ICU of Renmin Hospital of Wuhan University and Wuhan Jin Yin-tan Hospital between December 24, 2019, and March 12, 2020. Eleven patients who had been diagnosed with critically ill COVID-19 according to the World Health Organization interim guidance, received invasive ventilation, and were finally successfully weaned from it, were enrolled in our study. Their presenting symptoms, comorbidity conditions, laboratory values, ICU course, ventilator parameters, treatments, and relative complications were recorded.Of 108 critically ill COVID-19 patients who received invasive ventilation, 11 patients who underwent tracheal extubation or terminal weaning were included. The mean age of the 11 patients was 52.8 years (range, 38-70 years), 8 (72.7%) were male, and 2 were health care workers. The median time from onset of symptoms to dyspnea was 6.6 days (range, 3-13 days), and the median duration of IMV was 15.7 days (range, 6-29 days). All 11 patients presented with acute severe hypoxemic respiratory failure and received IMV, and 1 patient switched to extracorporeal membrane oxygenation assistance. A lung-protective strategy with lower tidal volume ventilation and proper driving pressure is the main strategy of IMV. All patients had extrapulmonary manifestations, including acute kidney injury, hepatic dysfunction, myocardial damage, and/or lymphopenia. Hospital-acquired infections occurred in 7 (63.6%) patients.Critical COVID-19 illness is characterized by acute hypoxemic respiratory failure and subsequent dysfunction of other organs with a high mortality rate. Correct ventilation strategies and other clinical strategies to improve oxygenation based on the skilled trained group and the availability of equipment are the key methods to rescue lives.
2019 年 12 月,中国武汉首次报告了冠状病毒病(COVID-19)疫情。关于接受有创机械通气(IMV)的危重症 COVID-19 患者的具体信息很少。本研究旨在描述接受有创机械通气并成功撤机的危重症 COVID-19 患者的临床过程和并发症。
本回顾性研究纳入了 2019 年 12 月 24 日至 2020 年 3 月 12 日期间,武汉大学人民医院 3 个重症监护病房(ICU)和 1 个亚 ICU 以及武汉金银潭医院收治的符合世界卫生组织临时指南诊断的危重症 COVID-19 患者。根据世界卫生组织的临时指南,11 例患者被诊断为危重症 COVID-19,接受了有创通气,并最终成功撤机,纳入本研究。记录了他们的临床表现、合并症、实验室值、入住 ICU 期间的情况、呼吸机参数、治疗方法和相关并发症。
在接受有创通气的 108 例危重症 COVID-19 患者中,有 11 例患者进行了气管拔管或终末脱机。11 例患者的平均年龄为 52.8 岁(范围 38-70 岁),8 例(72.7%)为男性,2 例为医务人员。从症状出现到呼吸困难的中位时间为 6.6 天(范围 3-13 天),有创机械通气的中位时间为 15.7 天(范围 6-29 天)。所有 11 例患者均表现为急性严重低氧性呼吸衰竭,并接受了有创机械通气,1 例患者转为体外膜氧合辅助。低潮气量通气和适当驱动压力的肺保护性策略是有创机械通气的主要策略。所有患者均有肺外表现,包括急性肾损伤、肝功能障碍、心肌损伤和/或淋巴细胞减少症。7 例(63.6%)患者发生医院获得性感染。
危重症 COVID-19 疾病的特征是急性低氧性呼吸衰竭,随后其他器官功能障碍,死亡率高。基于熟练医护团队和设备的可用性,正确的通气策略和其他改善氧合的临床策略是挽救生命的关键方法。